Study Subjects 1 Sample Clauses

Study Subjects 1. 3 Subjekty hodnocení The estimated number of subjects to be enrolled by the Investigator is ( ). Detailed criteria of subjects to be enrolled in the Study are provided in the Protocol. As the Study is part of a multicenter trial, PSI and the Sponsor may request the Investigator to stop enrolment at any time. . Předpokládaný počet pacientů, kteří budou Hlavním zkoušejícím zařazeni do Studie, je ( ''). Podrobná kritéria pro zařazování subjektů do Studie jsou uvedena v Protokolu. Vzhledem k tomu, že Studie je součástí multicentrického hodnocení, PSI a Zadavatel mohou kdykoli požadovat, aby Hlavní zkoušející ukončil nábor pacientů do Studie.
Sample 1
AutoNDA by SimpleDocs
Study Subjects 1. Soggetti dello Studio Categories of data subjects whose personal data is transferred: Study subjects, pregnant partners Categorie di interessati i cui dati personali sono trasferiti: Xxxxxxxx dello studio, partner in gravidanza Categories of personal data transferred: Subject identification code (SIC), age/year of birth Categorie di dati personali trasferiti: Codice identificativo del soggetto (SIC), età/anno di nascita Sensitive data transferred (if applicable) and applied restrictions or safeguards: - Categories of personal data: race/ethnicity; consumption of tobacco, alcohol and recreational drugs, assistance, physical exercise, diet and eating habits, leisure; lifestyle; Information derived from the testing or examination of a body part or bodily substance, including from genetic data and biological samples; disease, disability, disease risk, medical history, clinical treatment or the physiological or biomedical state of the data subject independent of its source; vaccination plans, vital signs, vital status; contraception, data on ongoing and outcome of pregnancy. - Restrictions or safeguards: pseudonymization, data minimisation, purpose limitation, restricted access, no unauthorized onward transfers, limited retention. - Dati sensibili trasferiti (se del caso) e limitazioni o garanzie applicate Categorie di dati personali: razza/etnia; consumo di tabacco, alcol e droghe ricreative, assistenza, esercizio fisico, dieta e abitudini alimentari, tempo libero; stile di vita; informazioni derivate da test o esami di una parte del corpo o di una sostanza corporea, compresi i dati genetici e i campioni biologici; malattia, disabilità, rischio di malattia, anamnesi medica, trattamento clinico o stato fisiologico o biomedico dell'interessato, indipendentemente dalla fonte; piani di vaccinazione, parametri vitali, stato vitale; contraccezione, dati sull'andamento e sull'esito della gravidanza. - Limitazioni o garanzie: pseudonimizzazione, minimizzazione dei dati, limitazione delle finalità, accesso limitato, divieto di trasferimenti successivi non autorizzati, conservazione limitata. The frequency of the transfer: Continuous Frequenza del trasferimento: Continuativa Nature of the processing: Collection/obtainment, storage, alternation, transfer/transmission, de- identification (pseudonymisation, anonymisation, aggregation, masking, removal of data elements), deletion/destruction Natura del trattamento: Raccolta/ottenimento, conservazione, alternanza, trasferime...
Sample 1
Study Subjects 1. 3 Subjekty hodnocení The estimated number of subjects to be enrolled by the Investigator . Detailed criteria of subjects to be enrolled in the Study are provided in the Protocol. As the Study is part of a multicenter trial, the Sponsor may request the Investigator to stop enrolment at any time. Předpokládaný počet pacientů, kteří budou Hlavním zkoušejícím zařazeni do Studie, '. Podrobná kritéria pro zařazování subjektů do Studie jsou uvedena v Protokolu. Vzhledem k tomu, že Studie je součástí multicentrického hodnocení, Zadavatel smí kdykoli požadovat, aby Hlavní zkoušející ukončil nábor pacientů do Studie.
Sample 1
Study Subjects 1. 3 Subjekty hodnocení The estimated number of subjects to be enrolled by the Investigator is 3. Detailed criteria of subjects to be enrolled in the Study are provided in the Protocol. As the Study is part of a multicenter trial, PSI and the Sponsor may request the Investigator to stop enrolment at any time. Předpokládaný počet pacientů, kteří budou Hlavním zkoušejícím zařazeni do Studie, je 3. Podrobná kritéria pro zařazování subjektů do Studie jsou uvedena v Protokolu. Vzhledem k tomu, že Studie je součástí multicentrického hodnocení, PSI a Zadavatel mohou kdykoli požadovat, aby Hlavní zkoušející ukončil nábor pacientů do Studie.
Sample 1
Study Subjects 1. 3 Subjekty hodnocení The estimated number of subjects to be enrolled by the Investigator is . Detailed criteria of subjects to be enrolled in the Study are provided in the Protocol. As the Study is part of a multicenter trial, PSI and the Sponsor may, through consultation with the Investigator and the Institution, adjust the estimate of Study Subjects number or timeframe and shall retain the right to request the Investigator to stop enrolment at any time. Předpokládaný počet pacientů, kteří budou Hlavním zkoušejícím zařazeni do Studie, je . Podrobná kritéria pro zařazování subjektů do Studie jsou uvedena v Protokolu. Vzhledem k tomu, že Studie je součástí multicentrického hodnocení, PSI a Zadavatel mohou na základě konzultací s Hlavním zkoušejícím a Poskytovatelem zdravotních služeb upravit předpokládaný počet Subjektů hodnocení nebo časový rozvrh a i nadále si ponechávají právo kdykoli požadovat, aby Hlavní zkoušející ukončil nábor pacientů do Studie.
Sample 1
Study Subjects 1. 3 Účastníci Štúdie
Sample 1
Study Subjects 1. 3 Subjekty hodnocení
Sample 1
AutoNDA by SimpleDocs
Study Subjects 1. 3 Subjekty hodnocení The estimated number of subjects to be enrolled by the Investigator is . Detailed criteria of subjects to be enrolled in the Study are provided in the Protocol. As the Study is part of a multicenter trial, PSI and the Sponsor may Předpokládaný počet pacientů, kteří budou Hlavním zkoušejícím zařazeni do Studie, je . Podrobná kritéria pro zařazování subjektů do Studie jsou uvedena v Protokolu. Vzhledem k tomu, že Studie je součástí multicentrického hodnocení, PSI a Zadavatel mohou kdykoli request the Investigator to stop enrolment at any time. požadovat, aby Hlavní zkoušející ukončil nábor pacientů do Studie.
Sample 1

Related to Study Subjects 1

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Study Population ‌ Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Treatment Program Testing The Employer may request or require an employee to undergo drug and alcohol testing if the employee has been referred by the employer for chemical dependency treatment or evaluation or is participating in a chemical dependency treatment program under an employee benefit plan, in which case the employee may be requested or required to undergo drug or alcohol testing without prior notice during the evaluation or treatment period and for a period of up to two years following completion of any prescribed chemical dependency treatment program.

  • Geotechnical Investigation Perform in accordance with the City Design Manual and other City requirements as designated in writing by the Director.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

  • Geological and Archeological Specimens If, during the execution of the Work, the Contractor, any Subcontractor, or any servant, employee, or agent of either should uncover any valuable material or materials, such as, but not limited to, treasure trove, geological specimens, archival material, archeological specimens, or ore, the Contractor acknowledges that title to the foregoing is vested in the Owner. The Contractor shall notify the Owner upon the discovery of any of the foregoing, shall take reasonable steps to safeguard it, and seek further instruction from the Design Professional. Any additional cost incurred by the Contractor shall be addressed under the provision for changed conditions. The Contractor agrees that the Geological and Water Resources Division and the Historic Preservation Division of the Georgia Department of Natural Resources may inspect the Work at reasonable times.

  • Tuberculosis Examination The examination shall consist of an approved intradermal tuberculosis test, which, if positive, shall be followed by an X-ray of the lungs. Nothing in Sections 5163 to 5163.2, inclusive, shall prevent the governing body of any city or county, upon recommendation of the local health officer, from establishing a rule requiring a more extensive or more frequent examination than required by Section 5163 and this section. § 5163.2. Technician taking X-ray film; Interpretation of X-ray The X-ray film may be taken by a competent and qualified X-ray technician if the X-ray film is subsequently interpreted by a licensed physician and surgeon.

  • Feasibility Study Buyer will, at Buyer's expense and within ____ days from Effective Date ("Feasibility Study Period"), determine whether the Property is suitable, in Buyer's sole and absolute discretion, for ___________________ use. During the Feasibility Study Period, Buyer may conduct a Phase I environmental assessment and any other tests, analyses, surveys and investigations ("Inspections") that Buyer deems necessary to determine to Buyer's satisfaction the Property's engineering, architectural and environmental properties; zoning and zoning restrictions; subdivision statutes; soil and grade; availability of access public roads, water, and other utilities; consistency with local, state and regional growth management plans, availability of permits, government approvals, and licenses; and other inspections that Buyer deems appropriate to determine the Property's suitability for the Buyer's intended use. If the Property must be rezoned, Buyer will obtain the rezoning from the appropriatx xxxernment agencies. Seller will sign all documents Buyer is required to file in connection with development or rezoning approvals. Seller gives Buyer, its agents, contractors and assigns, the right to enter the Property at any time during the Feasibility Study Period for the purpose of conducting inspections; provided, however, that Buyer, its agents, contractors and assigns enter the Property and conduct inspections at their own risk. Buyer will indemnify and hold Seller harmless from xxxxes, damages, costs, claims and expenses of any nature, including attorney's fees, expenses and liability incurred in application for rezoning or related proceedings, and from liability to any person, arising from the conduct of any and all inspections of any work authorized by Buyer. Buyer will not engage in any activity that xxxxx result in a construction lien being filed against the Property without Seller's prior written consent. If this transaction does not close, Buyer will, at Buyer's expense, (1) repair all damages to the Property resulting from the Inspections and return the Property to the condition it was in prior to conduct of the Inspections, and (2) release to Seller all reports and other work generated as a result of the Inspections. Buyer will deliver written notice to Seller prior to the expiration of the Feasibility Study Period of Buyer's determination of whether or not the Properxx xx acceptable. Buyer's failure to comply with this notice requirement will constitute acceptance of the Property as suitable for Buyer's intended use in its "as is" condition. If the Property is unacceptable to Buyer and written notice of this fact is timely delivered to Seller, this Contract will be deemed terminated as of the day after the Feasibility Study period ends and Buyer's deposit(s) will be returned after Escrow Axxxx receives proper authorization form all interested parties.

Time is Money Join Law Insider Premium to draft better contracts faster.